Oncology – Gastrointestinal
RCT | First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma
3 Feb, 2023 | 14:02h | UTC
M-A | Treatment- and immune-related AEs of checkpoint inhibitors in esophageal or gastroesophageal junction cancer
3 Feb, 2023 | 13:55h | UTC
M-A | Major complications and mortality after resection of intrahepatic cholangiocarcinoma
3 Feb, 2023 | 13:43h | UTC
M-A | Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer
2 Feb, 2023 | 14:36h | UTC
M-A | Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma
31 Jan, 2023 | 13:42h | UTC
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
M-A | Proximal gastrectomy with double-tract-reconstruction vs. total gastrectomy in gastric and gastroesophageal junction cancer patients
27 Jan, 2023 | 11:54h | UTC
RCT | Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion
26 Jan, 2023 | 12:03h | UTC
RCT | Preoperative chemotherapy reduced recurrence in operable colon cancer
25 Jan, 2023 | 11:29h | UTCEditorial: FOxTROT: Are We Ready to Dance? – Journal of Clinical Oncology
News Release: Chemotherapy before surgery cuts risk of colon cancer returning, trial finds – Cancer Research UK
Commentary: New treatment strategy cuts risk of bowel cancer returning by 28% – The Guardian
Commentary from one of the authors on Twitter (thread – click for more)
🥁🥁🥁Tweetorial
FOxTROT, the 1st ph 3 RCT of neoadjuvant chemo (NAC) in locally advanced colon cancer
We report that NAC is
✅deliverable and safe
✅led to statistically significant reduction in cancer recurrence than upfront surgery
A 🧵 (1/14)#crcsmhttps://t.co/y1hU6qWdXF— Jenny Seligmann (@JenSeligmann) January 20, 2023
Cohort Study | Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy in 120 000 repeated screening colonoscopies
23 Jan, 2023 | 13:36h | UTCCommentaries:
Prevalence of Colorectal Cancers Low 10 Years Following Negative Screening Test – HCP Live
Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy – HealthDay
Commentary on Twitter
Large registry-based study finds strong potential for risk-adapted #colorectalcancer screening, suggests extension of screening endoscopy intervals beyond 10 years may be warranted particularly in asymptomatic female and younger participants. https://t.co/fChg6DRyPw @DKFZ
— JAMA Internal Medicine (@JAMAInternalMed) January 17, 2023
RCT | Adjuvant S-1 compared with observation in resected biliary tract cancer
23 Jan, 2023 | 13:24h | UTCAdjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Nakachi et al – Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial https://t.co/E6y7a9dWNf#gitwitter #biliarytractcancer #onctwitter @OncoAlert #JCOG pic.twitter.com/WEBFXjIWce
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 20, 2023
Single-arm phase 2 study | Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
23 Jan, 2023 | 13:22h | UTCFutibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
FGFR2 fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. In a study, futibatinib, an FGFR inhibitor, induced responses (median, 9.7 months) in 42% of patients. https://t.co/FAXE2AnQ90 pic.twitter.com/9Fn9KxZxeg
— NEJM (@NEJM) January 19, 2023
Cohort Study | Hemicolectomy vs. appendectomy for patients with appendiceal neuroendocrine tumors 1–2 cm in size
23 Jan, 2023 | 13:21h | UTCHemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors – The ASCO Post
MRI anatomy of the rectum: key concepts important for rectal cancer staging and treatment planning
20 Jan, 2023 | 14:34h | UTC
Single-arm phase 1-2 study | Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer
20 Jan, 2023 | 14:31h | UTCSotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a phase 1–2 trial involving patients with advanced pancreatic cancer, sotorasib (a KRAS G12C inhibitor) resulted in a response in 21% of the patients and a median progression-free survival of 4 months. https://t.co/BUepIWvx65 pic.twitter.com/i1kugfC6Nq
— NEJM (@NEJM) December 21, 2022
RCT | Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer
20 Jan, 2023 | 14:19h | UTC
Commentary on Twitter
Single centre #RCT of surgery for T3/4 N+ #rectalcancer before or after 8 weeks of CRT
🧑🤝🧑350 patients
⚖️no difference locoregional recurrence
Distant mets more common in delayed group at 5yrs
DFS and OS similar#some4surgery @SEIQuirurgica @asgbi https://t.co/4evsKNKKK1 pic.twitter.com/CxI0GJdG56— BJS Open (@BjsOpen) October 24, 2022
Study shows patients with circulating tumor DNA are at increased risk of relapse after surgery for resectable colorectal cancer
19 Jan, 2023 | 14:18h | UTCCommentary: Data Support ctDNA as a Prognostic Marker for Recurrence/Benefit in Colorectal Cancer – Cancer Network
Commentary on Twitter
In the observational arm of the CIRCULATE-Japan study, among patients with stage II-IV #ColorectalCancer, those with the presence of circulating #tumorDNA post-tumor resection have a high recurrence risk & are likely to benefit from adjuvant #chemotherapyhttps://t.co/hKlRt1ZW6T
— Nature Medicine (@NatureMedicine) January 17, 2023
Consensus Paper | Management of early-onset colorectal cancer
19 Jan, 2023 | 14:14h | UTC
ACG Clinical Guideline | Diagnosis and management of gastrointestinal subepithelial lesions
18 Jan, 2023 | 14:39h | UTC
M-A | Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival?
17 Jan, 2023 | 13:07h | UTC
RCT | Adjuvant nab-Paclitaxel + Gemcitabine in resected pancreatic ductal adenocarcinoma
10 Jan, 2023 | 14:13h | UTC
RCT | Neoadjuvant chemotherapy with CAPOX vs. chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia
10 Jan, 2023 | 14:09h | UTC
ASCO Guideline | Immunotherapy and targeted therapy for advanced gastroesophageal cancer
9 Jan, 2023 | 14:40h | UTC
Phase 1-2 study | Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C
9 Jan, 2023 | 14:04h | UTCAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Advanced Colorectal Cancer Treatment Targets KRAS Gene With Drug Combo – Memorial Sloan Kettering Cancer Center
Commentary on Twitter
In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody. https://t.co/nCoEPeV9oB pic.twitter.com/FCHxU9WCin
— NEJM (@NEJM) December 21, 2022
M-A | Laparoscopic vs. open pancreatoduodenectomy in patients with periampullary tumors
9 Jan, 2023 | 14:02h | UTCLaparoscopic versus Open Pancreatoduodenectomy in Patients with Periampullary Tumors: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)